Yixintang Pharmaceutical Group Co., Ltd. held its 3rd Extraordinary General Meeting of 2025 on 13 November 2025, approved the appointment of Jiang Ning, non-independent director, Zhang Yong, non-independent director, Ruan Aixiang, non-independent director, Long Chao, independent director, Liu Lifang, independent director, Shi Qian, independent director.
Yixintang Pharmaceutical Group Co., Ltd., formerly Yunnan Hongxiang Yixintang Pharmaceutical Co., Ltd., is a China-based company principally engaged in the pharmaceutical chain retailing and pharmaceutical wholesaling businesses. The Companyâs main products include traditional Chinese medicines, western medicines, medical equipment, birth control products and disinfection products, among others. The Company distributes its products through regular chain drugstores. The Company mainly operates its business in domestic market, with southwest area of China as its main market.
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
